NCT02112110View on ClinicalTrials.gov

Absolute Bioavailability of BMS-791325

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Hepatitis C Virus Infection
Interventions
DRUG

BMS-791325

DRUG

[13C]-BMS-791325

Trial Locations (1)

NG11 6JS

Local Institution, Nottingham

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02112110 - Absolute Bioavailability of BMS-791325 | Biotech Hunter | Biotech Hunter